Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial
Top Cited Papers
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 391 (10135), 2107-2115
- https://doi.org/10.1016/s0140-6736(18)31033-x
Abstract
No abstract availableFunding Information
- NIHR Health Technology Assessment programme (11_129_109)
This publication has 27 references indexed in Scilit:
- CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trialTrials, 2012
- Defining hematoma expansion in intracerebral hemorrhageNeurology, 2011
- The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trialThe Lancet, 2011
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialThe Lancet, 2010
- Options to Restrict Hematoma Expansion After Spontaneous Intracerebral HemorrhageStroke, 2010
- Determinants of Intracerebral Hemorrhage GrowthStroke, 2007
- User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliabilityNeuroImage, 2006
- Recombinant Activated Factor VII for Acute Intracerebral HemorrhageThe New England Journal of Medicine, 2005
- Early Hemorrhage Growth in Patients With Intracerebral HemorrhageStroke, 1997
- Enlargement of Spontaneous Intracerebral HemorrhageStroke, 1996